Murphy & Mullick Capital Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$208K Sell
5,486
-25
-0.5% -$1.15K 0.13% 142
2026
Q2
$264K Sell
5,511
-302
-5% -$13K 0.16% 118
2026
Q1
$214K Sell
5,813
-542
-9% -$25.7K 0.16% 130
2025
Q4
$323K Buy
6,355
+378
+6% +$19.3K 0.23% 96
2025
Q3
$331K Sell
5,977
-56
-0.9% -$3.28K 0.25% 89
2025
Q2
$286K Sell
6,033
-119
-2% -$8.09K 0.23% 96
2025
Q1
$427K Sell
6,152
-10
-0.2% -$826 0.41% 63
2024
Q4
$530K Hold
6,162
– – 0.49% 50

Other funds holding NVO

Murphy & Mullick Capital Management's NVO Position: Q3 2026 in Review

Murphy & Mullick Capital Management reduced its Novo Nordisk (NVO) stake by 0.45% in Q3 2026, selling an estimated $1.15K and leaving 5,486 shares worth $208K. The position accounts for 0.13% of the portfolio, ranked #142.

Murphy & Mullick Capital Management first reported a position in NVO in Q4 2024 and has held it in 8 quarters since. The position peaked at $530K in Q4 2024. 1,237 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

  • Murphy & Mullick Capital Management held 5,486 shares of Novo Nordisk worth $208K as of Q3 2026.
  • Murphy & Mullick Capital Management sold 25 Novo Nordisk shares in Q3 2026, an estimated $1.15K.
  • Novo Nordisk made up 0.13% of Murphy & Mullick Capital Management's portfolio in Q3 2026, its #142 holding.
  • Murphy & Mullick Capital Management first reported a position in Novo Nordisk in Q4 2024 and has held it in 8 quarters since.
  • Murphy & Mullick Capital Management's Novo Nordisk position peaked at $530K in Q4 2024.
  • 1,237 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q3 2026, filed 2 Nov 2026.